SAFE-PCI for Women

Conditions

Ischemic Symptoms, Percutaneous Coronary Intervention

Keywords

Female, urgent or elective percutaneous coronary intervention, PCI, diagnostic angiography

Brief summary

The hypothesis of the SAFE-PCI for women trial is that, compared with transfemoral PCI, transradial PCI will result in a significant reduction in bleeding and vascular complications. The primary objective is to compare the efficacy and feasibility of the transradial approach to percutaneous coronary intervention (PCI) in women compared with the transfemoral approach. This study is a multicenter, randomized, open-label active controlled study. Three thousand women undergoing urgent or elective PCI from at least 50 centers will be randomized to either transradial or transfemoral PCI. Patients who are enrolled at sites performing ad hoc PCI will be randomized before diagnostic angiography. A total of approximately 3000 women will be randomized to obtain a cohort of approximately 1800 patients undergoing PCI. The Data Safety Monitoring Board has alerted us that the bleeding event rate overall in our trial is very low, making it unlikely that there will be statistical power to show a difference between the randomized arms in the SAFE PCI for Women study using the BARC bleeding definition per protocol. Based on this statistical futility, the DSMB has recommended stopping enrollment. They also noted, however, that as this is not based on any safety issues, and since there are a variety of key secondary endpoints (contrast and radiation exposure, quality of life) that are of clinical and scientific interest, the DSMB left it to the discretion of the Steering Committee to continue enrollment to meet sufficient power for these outcomes. On March 1, 2013, the Steering Committee met to discuss these issues and voted to continue enrollment until the planned sample size for the Quality of Life substudy was met (300 patients).

Jennifer A. Rymer, Lisa A. Kaltenbach, Ajar Kochar, Connie N. Hess, Ian C. Gilchrist et al. (13 authors)

Circulation Cardiovascular Interventions2019-04-248 citations

10.1161/circinterventions.118.007086

Text messaging reminders for influenza vaccine in primary care: a cluster randomised controlled trial (TXT4FLUJAB)

Emily Herrett, Elizabeth Williamson, Tjeerd van Staa, Michael Rañopa, Caroline Free et al. (8 authors)

BMJ Open2016-02-0157 citations

10.1136/bmjopen-2015-010069

A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.

Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, Jorgensen JP, Mazzaferri EL, Jolly SS, Jacobs A, Newby LK, Gibson CM, Kong DF, Mehran R, Waksman R, Gilchrist IC, McCourt BJ, Messenger JC, Peterson ED, Harrington RA, Krucoff MW.

2014-08-01173 citations

10.1016/j.jcin.2014.04.007

Interventions

PROCEDURETransradial PCI

Transradial PCI

PROCEDURETransfemoral PCI

Transfemoral PCI

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Have the capacity to understand and sign an informed consent form * Age ≥ 18 years * Female patient undergoing urgent or elective PCI or undergoing diagnostic angiography to evaluate ischemic symptoms with the possibility of PCI

Exclusion criteria

* Peripheral arterial disease that prohibits vascular access * Bilateral abnormal Barbeau tests * Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (note that the opposite arm may be used for radial access in case a dialysis graft is present in one arm provided that the opposite arm has a normal Barbeau test) * International normalized ratio (INR) ≥ 1.5 in a patient treated with oral vitamin K antagonists (i.e., warfarin). * Receipt of oral Factor Xa or IIa inhibitors ≤ 24 hours prior to the procedure * Planned staged PCI within 30 days of index procedure * Valvular heart disease requiring valve surgery * Planned right-heart catheterization * Primary PCI for ST-segment elevation myocardial infarction * Presence of bilateral internal mammary artery coronary bypass grafts * Unable to provide informed consent * Participation in any investigational drug or device study currently or within 30 days prior to enrollment

Design outcomes

Primary

Measure	Time frame
Primary Efficacy Endpoint: Composite of BARC Types 2, 3, and 5 bleeding or vascular complications.	From first arterial access post-randomization to 72 hours or hospital discharge, whichever occurs first.
Primary Feasibility Endpoint: Procedural failure, defined as inability to complete the procedure from the assigned vascular access site.	From first arterial access post-randomization to 72 hours or hospital discharge, whichever occurs first.

Secondary

Measure	Time frame	Description
Procedure Duration, total radiation dose and total contrast volume	72 hours post randomization or hospital discharge (whichever occurs first)	To determine the effect of transradial PCI on procedure time, total radiation dose, and total contrast volume.
Resource Use, patient preferences and quality of life	Baseline, 72 hours post randomization or hospital discharge (whichever occurs first), 30 day	To determine the effect of transradial PCI on resource use, patient preferences, and quality of life.
30-day death, vascular complications, or repeat revascularization	30 day	To determine the effect of transradial PCI on 30-day death, vascular complications, or repeat revascularization.

Outcome results

None listed